Characteristics of the study population
Characteristics . | Low-risk category*; n = 297 . | Intermediate/high-risk category*; n = 651 . |
|---|---|---|
| HLA compatibility, no. (%) | ||
| Matched | 161 (54) | 320 (49) |
| One mismatch | 81 (27) | 167 (26) |
| Two or more mismatches | 55 (19) | 164 (25) |
| Median recipient age, y (range) | 37 (2-55) | 34 (1-62) |
| Donor-recipient sex, no. (%) | ||
| M-M | 104 (35) | 229 (35) |
| M-F | 78 (26) | 153 (24) |
| F-F | 54 (18) | 125 (19) |
| F-M | 61 (21) | 144 (22) |
| Pretransplantation CMV† exposure, no. (%) | 128 (43) | 307 (47) |
| Number of cells infused per kg body weight, × 108 (range) | 3.2 (0.7-30.0) | 3.6 (0.4-40.7) |
| Source of cells | ||
| Bone marrow | 296 | 555 |
| PBSC | 1 | 96 |
| Use of gancyclovir-fluconazole, no. (%) | ||
| Gancyclovir | 278 (94%) | 585 (90%) |
| Fluconazole | 254 (86%) | 541 (83%) |
Characteristics . | Low-risk category*; n = 297 . | Intermediate/high-risk category*; n = 651 . |
|---|---|---|
| HLA compatibility, no. (%) | ||
| Matched | 161 (54) | 320 (49) |
| One mismatch | 81 (27) | 167 (26) |
| Two or more mismatches | 55 (19) | 164 (25) |
| Median recipient age, y (range) | 37 (2-55) | 34 (1-62) |
| Donor-recipient sex, no. (%) | ||
| M-M | 104 (35) | 229 (35) |
| M-F | 78 (26) | 153 (24) |
| F-F | 54 (18) | 125 (19) |
| F-M | 61 (21) | 144 (22) |
| Pretransplantation CMV† exposure, no. (%) | 128 (43) | 307 (47) |
| Number of cells infused per kg body weight, × 108 (range) | 3.2 (0.7-30.0) | 3.6 (0.4-40.7) |
| Source of cells | ||
| Bone marrow | 296 | 555 |
| PBSC | 1 | 96 |
| Use of gancyclovir-fluconazole, no. (%) | ||
| Gancyclovir | 278 (94%) | 585 (90%) |
| Fluconazole | 254 (86%) | 541 (83%) |
Pretransplantation risk categories were defined as low-risk (chronic phase chronic myeloid leukemia [CML] and transplantation within 2 years of diagnosis; n = 297), intermediate-risk (chronic phase CML and transplantation more than 2 years after diagnosis; accelerated phase [AP] or blast crisis [BC]/remission CML and transplantation within 3 years after diagnosis; acute leukemia transplanted in remission; myelodysplastic syndrome-refractory anemia; n = 396) or high risk (blast crisis CML; accelerated phase or blast crisis/remission CML and transplantation more than 3 years from diagnosis; acute leukemia transplanted in relapse; myelodysplastic syndrome other than refractory anemia; n = 255) according to published survival data9,11,19-26
Cytomegalovirus